308 related articles for article (PubMed ID: 16828069)
1. Characterization of a C57BL/6 congenic mouse strain of mucopolysaccharidosis type IIIA.
Crawley AC; Gliddon BL; Auclair D; Brodie SL; Hirte C; King BM; Fuller M; Hemsley KM; Hopwood JJ
Brain Res; 2006 Aug; 1104(1):1-17. PubMed ID: 16828069
[TBL] [Abstract][Full Text] [Related]
2. Open field locomotor activity and anxiety-related behaviors in mucopolysaccharidosis type IIIA mice.
Lau AA; Crawley AC; Hopwood JJ; Hemsley KM
Behav Brain Res; 2008 Aug; 191(1):130-6. PubMed ID: 18453006
[TBL] [Abstract][Full Text] [Related]
3. Intracerebral injection of sulfamidase delays neuropathology in murine MPS-IIIA.
Savas PS; Hemsley KM; Hopwood JJ
Mol Genet Metab; 2004 Aug; 82(4):273-85. PubMed ID: 15308125
[TBL] [Abstract][Full Text] [Related]
4. Injection of recombinant human sulfamidase into the CSF via the cerebellomedullary cistern in MPS IIIA mice.
Hemsley KM; King B; Hopwood JJ
Mol Genet Metab; 2007 Mar; 90(3):313-28. PubMed ID: 17166757
[TBL] [Abstract][Full Text] [Related]
5. Development of motor deficits in a murine model of mucopolysaccharidosis type IIIA (MPS-IIIA).
Hemsley KM; Hopwood JJ
Behav Brain Res; 2005 Mar; 158(2):191-9. PubMed ID: 15698885
[TBL] [Abstract][Full Text] [Related]
6. Examination of intravenous and intra-CSF protein delivery for treatment of neurological disease.
Hemsley KM; Luck AJ; Crawley AC; Hassiotis S; Beard H; King B; Rozek T; Rozaklis T; Fuller M; Hopwood JJ
Eur J Neurosci; 2009 Mar; 29(6):1197-214. PubMed ID: 19302155
[TBL] [Abstract][Full Text] [Related]
7. Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: Diagnostic, clinical, and biological implications.
Yogalingam G; Hopwood JJ
Hum Mutat; 2001 Oct; 18(4):264-81. PubMed ID: 11668611
[TBL] [Abstract][Full Text] [Related]
8. Enzyme-replacement therapy from birth delays the development of behavior and learning problems in mucopolysaccharidosis type IIIA mice.
Gliddon BL; Hopwood JJ
Pediatr Res; 2004 Jul; 56(1):65-72. PubMed ID: 15128919
[TBL] [Abstract][Full Text] [Related]
9. Validation of a heparan sulfate-derived disaccharide as a marker of accumulation in murine mucopolysaccharidosis type IIIA.
King B; Savas P; Fuller M; Hopwood J; Hemsley K
Mol Genet Metab; 2006 Feb; 87(2):107-12. PubMed ID: 16352454
[TBL] [Abstract][Full Text] [Related]
10. Gastrointestinal pathology in a mouse model of mucopolysaccharidosis type IIIA.
Roberts AL; Howarth GS; Liaw WC; Moretta S; Kritas S; Lymn KA; Yazbeck R; Tran C; Fletcher JM; Butler RN; Byers S
J Cell Physiol; 2009 May; 219(2):259-64. PubMed ID: 19170061
[TBL] [Abstract][Full Text] [Related]
11. Identification of a mutation causing mucopolysaccharidosis type IIIA in New Zealand Huntaway dogs.
Yogalingam G; Pollard T; Gliddon B; Jolly RD; Hopwood JJ
Genomics; 2002 Feb; 79(2):150-3. PubMed ID: 11829484
[TBL] [Abstract][Full Text] [Related]
12. Correction of mucopolysaccharidosis type IIIA somatic and central nervous system pathology by lentiviral-mediated gene transfer.
McIntyre C; Byers S; Anson DS
J Gene Med; 2010 Sep; 12(9):717-28. PubMed ID: 20683858
[TBL] [Abstract][Full Text] [Related]
13. Embryonic stem cell-derived glial precursors as a vehicle for sulfamidase production in the MPS-IIIA mouse brain.
Robinson AJ; Zhao G; Rathjen J; Rathjen PD; Hutchinson RG; Eyre HJ; Hemsley KM; Hopwood JJ
Cell Transplant; 2010; 19(8):985-98. PubMed ID: 20350350
[TBL] [Abstract][Full Text] [Related]
14. Effect of high dose, repeated intra-cerebrospinal fluid injection of sulphamidase on neuropathology in mucopolysaccharidosis type IIIA mice.
Mader KM; Beard H; King BM; Hopwood JJ
Genes Brain Behav; 2008 Oct; 7(7):740-53. PubMed ID: 18518922
[TBL] [Abstract][Full Text] [Related]
15. Impact of high-dose, chemically modified sulfamidase on pathology in a murine model of MPS IIIA.
Rozaklis T; Beard H; Hassiotis S; Garcia AR; Tonini M; Luck A; Pan J; Lamsa JC; Hopwood JJ; Hemsley KM
Exp Neurol; 2011 Jul; 230(1):123-30. PubMed ID: 21515264
[TBL] [Abstract][Full Text] [Related]
16. Improvement in behaviour after substrate deprivation therapy with rhodamine B in a mouse model of MPS IIIA.
Roberts AL; Rees MH; Klebe S; Fletcher JM; Byers S
Mol Genet Metab; 2007; 92(1-2):115-21. PubMed ID: 17681480
[TBL] [Abstract][Full Text] [Related]
17. Functional correction of CNS lesions in an MPS-IIIA mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes.
Fraldi A; Hemsley K; Crawley A; Lombardi A; Lau A; Sutherland L; Auricchio A; Ballabio A; Hopwood JJ
Hum Mol Genet; 2007 Nov; 16(22):2693-702. PubMed ID: 17725987
[TBL] [Abstract][Full Text] [Related]
18. Long-term individual housing in C57BL/6J and DBA/2 mice: assessment of behavioral consequences.
Võikar V; Polus A; Vasar E; Rauvala H
Genes Brain Behav; 2005 Jun; 4(4):240-52. PubMed ID: 15924556
[TBL] [Abstract][Full Text] [Related]
19. Mouse model of Sanfilippo syndrome type B: relation of phenotypic features to background strain.
Gografe SI; Garbuzova-Davis S; Willing AE; Haas K; Chamizo W; Sanberg PR
Comp Med; 2003 Dec; 53(6):622-32. PubMed ID: 14727810
[TBL] [Abstract][Full Text] [Related]
20. Exocytosis is impaired in mucopolysaccharidosis IIIA mouse chromaffin cells.
Keating DJ; Winter MA; Hemsley KM; Mackenzie KD; Teo EH; Hopwood JJ; Brooks DA; Parkinson-Lawrence EJ
Neuroscience; 2012 Dec; 227():110-8. PubMed ID: 23022219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
